The Leukemia & Lymphoma Society
1311 Mamaroneck Avenue
194 articles with The Leukemia & Lymphoma Society
Verastem Oncology Announces Collaboration with The Leukemia & Lymphoma Society to Accelerate Development of Duvelisib for the Treatment of Peripheral T-Cell Lymphoma
Verastem, Inc. today announced a collaboration with The Leukemia & Lymphoma Society® (LLS), to accelerate the development of duvelisib for the treatment of patients with peripheral T-cell lymphoma
The costs to treat a blood cancer are higher than costs for other cancers, and the costs incurred by a patient diagnosed with a blood cancer do not return to pre-cancer levels, according to a Milliman study commissioned by The Leukemia & Lymphoma Society (LLS).
10/25/2018What is presumably good humor, Cambridge, Mass.-based Syros Pharmaceuticals held its third annual Lab Olympics, where various executives in the company competed in a range of contests that included a race to put on safety equipment and accuracy in pipetting.
Schwartz Ward Family Foundation commits $1,175,000 to research in CAR T-cell immunotherapy in myeloma and novel therapy for lymphoma
LLS is leading the way to cancer cures, during Blood Cancer Awareness Month and beyond
Sutro Biopharma, Inc., and The Leukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s CD74-targeting antibody-drug conjugate, to treat relapsed and/or refractory multiple myeloma and non-Hodgkin’s lymphoma.
Female scientists lead scorers among 32 grant awardees in annual research competition held by Canada's only nonprofit health agency dedicated to all blood cancers.
The Leukemia & Lymphoma Society Greater Bay Area Chapter to Host World Class Sailing Event with Notable Speakers
The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter will host the Leukemia Cup Regatta on October 20 and 21 at the Corinthian Yacht Club in Tiburon, CA.
The Leukemia & Lymphoma Society (LLS) Announces Board of Directors Appointments and New Chief Operating Officer
World's largest blood cancer non-profit boasts addition of leading cancer researchers in its commitment to finding cures
The Leukemia & Lymphoma Society's Man & Woman of the Year Campaign Breaks Fundraising Records for Cancer Cures
10-week philanthropic competition raises $45 million
Bring light to someone who has been touched by the darkness of cancer on National Random Acts of Light Day, June 13
The Leukemia & Lymphoma Society celebrates year three of movement to support cancer patients and survivors; US Air Force vet surprised and honored at professional soccer event
The Leukemia & Lymphoma Society creates new generation of givers through unique Students of the Year Campaign
More Progress on LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment
The U.S. Food and Drug Administration (FDA) granted tisagenlecleucel (Kymriah®) its second approval to treat patients with diffuse large B-cell lymphoma (DLBCL).
The Harry T. Mangurian Jr. Foundation continues to fuel The Leukemia & Lymphoma Society (LSS) ambitious attack on this deadly blood cancer.
The Leukemia & Lymphoma Society (LLS) is shining a spotlight on the women in science who are helping to lead these advances.
Commitment to Curing Cancer: High School Fundraising Campaign Raises $192,000+ in Seven Weeks For The Leukemia & Lymphoma Society
Arnav Verma and Anoushka Dave of Team Cut Out Cancer named 2018 Students of the Year winners.
The Leukemia Lymphoma Society Achieves New Milestones in Offensive Against Acute Myeloid Leukemia, Deadly Blood Cancer
More than 150 patients are now enrolled in this innovative trial which aims to find new treatments for a blood cancer that has not seen significant treatment improvements in almost 40 years.
Neximmune and the Leukemia & Lymphoma Society Enter Partnership for the Development of AIM ACT in AML Patients
This will advance the Company’s novel cellular immunotherapy into Phase I clinical testing for patients with high risk AML who have relapsed after an allogeneic hematopoietic stem cell transplant.
The Leukemia & Lymphoma Society Release: FDA Approval Of Targeted Therapy For Acute Myeloid Leukemia Is A Significant Advance For Deadly Blood Cancer
Selvita And The Leukemia & Lymphoma Society Announce Partnership To Advance SEL120 Into Phase I For AML Patients